Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Gwenn Hansen Sells 1,452 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.00, for a total value of $36,300.00. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at $2,930,675. This represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.47, for a total value of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded down $0.53 during midday trading on Friday, reaching $24.42. 4,318,315 shares of the stock traded hands, compared to its average volume of 2,100,443. The company’s 50 day moving average is $25.11 and its 200 day moving average is $21.16. Nurix Therapeutics, Inc. has a one year low of $9.71 and a one year high of $28.23. The stock has a market capitalization of $2.67 billion, a PE ratio of 10.57 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $5.33. The company had revenue of $673.06 million for the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post 0.85 EPS for the current year.

Hedge Funds Weigh In On Nurix Therapeutics

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in Nurix Therapeutics by 95.4% in the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after buying an additional 620 shares during the last quarter. Nykredit A S bought a new position in Nurix Therapeutics during the second quarter valued at $32,000. Integrated Wealth Concepts LLC bought a new position in Nurix Therapeutics during the second quarter valued at $33,000. KBC Group NV bought a new position in Nurix Therapeutics during the first quarter valued at $34,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at $53,000.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NRIX. Wall Street Zen raised shares of Nurix Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Mizuho upped their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Oppenheimer upped their target price on shares of Nurix Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.79.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.